Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pyridoxal-5-phosphate (P.L.P.), the biologically active form of vitamin B6, is a coenzyme in 150 enzymatic reactions, including amino acid, carbohydrate, and lipid metabolism. Neurotransmitter production and breakdown depend on it. Additionally, it functions as an antioxidant by suppressing reactive oxygen species and mitigating the development of advanced glycation end products. Humans recycle P.L.P. from dietary B6 vitamins, and this molecule has been related to various clinically relevant diseases. Pyridoxine as an additional therapy for type 2 diabetes will be examined in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes

NCT06376240

Type 2 Diabetes Microvascular Function Retinopathy, Diabetic +2 more

RECRUITING NA

The Effects of Leucine and Isoleucine on Glucose Metabolism

NCT02634164

Hyperglycemia

COMPLETED NA

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

NCT00703989

Type 1 Diabetes

COMPLETED NA

The Effect of Vitamin K Supplementation on Glucose Metabolism

NCT00960973

Diabetes Prediabetic State

COMPLETED PHASE4

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

NCT00446810

Diabetes Mellitus, Type 2

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Numerous organs might suffer long-term harm, malfunction, and failure as a result of type 2 diabetes. While the illness may initially cause weight loss, frequent urination, thirst, and hazy vision, the long-term repercussions may include the gradual onset of specific issues such as cardiovascular disease (CVD), retinopathy, which may culminate in blindness, and renal disease. The risk of foot ulcers, Charcot joints, and symptoms of autonomic dysfunction, such as sexual dysfunction, is associated with renal failure and/or neuropathy. Diabetes and vitamin B6 have both been linked. It is not apparent, therefore, whether diabetes is a consequence of low P.L.P. levels, a cause, or both. According to some study, diabetes may develop as a consequence of low P.L.P. levels, however other studies suggest that diabetes decreases P.L.P. levels. Although the physiological and molecular pathways behind these beneficial effects on diabetic pathology and related repercussions are not completely understood, multiple investigations have demonstrated that B6 therapy has good effects. There are numerous ways that pyridoxal 5-phosphate deficiency affects diabetes. As an essential element for numerous enzymes that contribute to this process, pyridoxal-5-phosphate can, for example, influence the route that converts tryptophan into niacin. It has been proven that the metabolites produced when this pathway is damaged lessen the bioactivity of insulin and cause insulin resistance, a T2D symptom . Pyridoxal-5-phosphate may influence insulin resistance via modulating the expression of adipogenesis-related genes. The degradation of co-enzyme-dependent enzymes like (C.B.S.) and (C.G.L.), which rely on pyridoxal-5-phosphate, may also promote insulin resistance via elevating homocysteine levels .

This research intends to examine the impact of pyridoxine adjuvant treatment on the blood glucose level in type 2 diabetes patients.

This is a randomized controlled open-label interventional study. T2DM patients who receive either (metformin with pyridoxine) or (metformin only) daily and T2DM patients treated with non-pharmacological therapy (lifestyle modification) will be included in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Newly diagnosed patients with T2DM, treated with non-pharmacological therapy (lifestyle modification).

Group Type OTHER

non-pharmacological therapy

Intervention Type OTHER

non-pharmacological therapy (healthy lifestyle modifications)

Metformin only group

T2DM patients treated with metformin 500 mg/day in addition to non-pharmacological therapy (lifestyle modification)

Group Type ACTIVE_COMPARATOR

Metformin 500 mg/day

Intervention Type DRUG

Metformin 500 mg/day in addition to non-pharmacological therapy

non-pharmacological therapy

Intervention Type OTHER

non-pharmacological therapy (healthy lifestyle modifications)

Combination group

T2DM patients treated with metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy (lifestyle modification)

Group Type EXPERIMENTAL

Metformin 500 mg/day

Intervention Type DRUG

Metformin 500 mg/day in addition to non-pharmacological therapy

Metformin 500 mg/day plus vitamin B6 300 mg/day

Intervention Type COMBINATION_PRODUCT

Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy

non-pharmacological therapy

Intervention Type OTHER

non-pharmacological therapy (healthy lifestyle modifications)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin 500 mg/day

Metformin 500 mg/day in addition to non-pharmacological therapy

Intervention Type DRUG

Metformin 500 mg/day plus vitamin B6 300 mg/day

Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy

Intervention Type COMBINATION_PRODUCT

non-pharmacological therapy

non-pharmacological therapy (healthy lifestyle modifications)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Metformin group Combination group control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 Diabetes mellitus newly diagnosed patient with age (Above 30) years.
* HbA1c less than or equal to 7.5%.

Exclusion Criteria

* Type 1 Diabetes mellitus.
* Concomitant chronic diseases (Rheumatoid arthritis, anemia, asthma, endocrine disorders, renal failure, alcoholics, and patient on anti-T.B. or anti-epileptics).
* Females should be neither pregnant nor on oral contraceptive drugs.
* Not taking any vitamin or mineral supplementation.
* Should have no history of recent acute infection (within the previous two weeks).

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No